MX2021014540A - Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama. - Google Patents
Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama.Info
- Publication number
- MX2021014540A MX2021014540A MX2021014540A MX2021014540A MX2021014540A MX 2021014540 A MX2021014540 A MX 2021014540A MX 2021014540 A MX2021014540 A MX 2021014540A MX 2021014540 A MX2021014540 A MX 2021014540A MX 2021014540 A MX2021014540 A MX 2021014540A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- breast cancer
- same
- leuprolide acetate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 108010000817 Leuprolide Proteins 0.000 title 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical group CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 title 1
- 229960004338 leuprorelin Drugs 0.000 title 1
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853153P | 2019-05-27 | 2019-05-27 | |
| PCT/IB2020/054984 WO2020240417A1 (en) | 2019-05-27 | 2020-05-26 | Leuprolide acetate compositions and methods of using the same to treat breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014540A true MX2021014540A (es) | 2022-04-12 |
Family
ID=70922081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014540A MX2021014540A (es) | 2019-05-27 | 2020-05-26 | Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12453754B2 (enExample) |
| EP (1) | EP3975990A1 (enExample) |
| JP (1) | JP7664855B2 (enExample) |
| KR (1) | KR20220041782A (enExample) |
| CN (1) | CN114144169A (enExample) |
| AR (1) | AR119021A1 (enExample) |
| AU (1) | AU2020284587B2 (enExample) |
| BR (1) | BR112021023904A2 (enExample) |
| CA (1) | CA3141456A1 (enExample) |
| EA (1) | EA202193257A1 (enExample) |
| IL (1) | IL288503A (enExample) |
| MX (1) | MX2021014540A (enExample) |
| PH (1) | PH12021552976A1 (enExample) |
| SG (1) | SG11202112888RA (enExample) |
| TW (1) | TWI757753B (enExample) |
| UY (1) | UY38717A (enExample) |
| WO (1) | WO2020240417A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114144169A (zh) | 2019-05-27 | 2022-03-04 | 托尔玛国际有限公司 | 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法 |
| DK4135830T3 (da) | 2020-12-23 | 2024-10-28 | Tolmar International Ltd | Systemer og fremgangsmåder til blanding af sprøjteventilanordninger |
| CN115518144A (zh) * | 2021-06-26 | 2022-12-27 | 王婧宜 | 一种含有亮丙瑞林或其衍生物的口服药物组合物 |
| USD1029245S1 (en) | 2022-06-22 | 2024-05-28 | Tolmar International Limited | Syringe connector |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| JP4259610B2 (ja) | 1994-04-08 | 2009-04-30 | キューエルティー・ユーエスエイ・インコーポレーテッド | 液体デリバリー組成物 |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
| WO2007084460A2 (en) | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
| DK3660073T3 (da) * | 2007-02-15 | 2023-09-18 | Tolmar International Ltd | Poly(lactid-co-glycolid) med lav sprængning |
| DE202009010095U1 (de) | 2009-07-24 | 2009-10-22 | Chang, Ti-Li, Houli | Verbindungsvorrichtung für einen auswechselbaren, abgeschlossenen Sekret-Absaugkatheter |
| IL301603A (en) * | 2011-10-14 | 2023-05-01 | Genentech Inc | Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient |
| CN114144169A (zh) | 2019-05-27 | 2022-03-04 | 托尔玛国际有限公司 | 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法 |
| KR102162217B1 (ko) | 2020-05-07 | 2020-10-06 | 주식회사 파인비엠 | 스태틱믹서를 갖는 연결장치를 구비한 시린지 결합 키트 |
| DK4135830T3 (da) | 2020-12-23 | 2024-10-28 | Tolmar International Ltd | Systemer og fremgangsmåder til blanding af sprøjteventilanordninger |
| AU2022331238A1 (en) | 2021-08-19 | 2024-02-01 | Carefusion 303, Inc. | Pivc-integrated hemolysis-reduction accessories with anti-spillage component for direct blood draw |
| FR3131618A1 (fr) | 2021-12-30 | 2023-07-07 | Parker Hannifin Emea Sarl | Dispositif de raccordement aseptique d’un tube |
-
2020
- 2020-05-26 CN CN202080052698.5A patent/CN114144169A/zh active Pending
- 2020-05-26 CA CA3141456A patent/CA3141456A1/en not_active Abandoned
- 2020-05-26 JP JP2021569057A patent/JP7664855B2/ja active Active
- 2020-05-26 BR BR112021023904A patent/BR112021023904A2/pt unknown
- 2020-05-26 EA EA202193257A patent/EA202193257A1/ru unknown
- 2020-05-26 PH PH1/2021/552976A patent/PH12021552976A1/en unknown
- 2020-05-26 AU AU2020284587A patent/AU2020284587B2/en active Active
- 2020-05-26 SG SG11202112888RA patent/SG11202112888RA/en unknown
- 2020-05-26 US US17/614,312 patent/US12453754B2/en active Active
- 2020-05-26 MX MX2021014540A patent/MX2021014540A/es unknown
- 2020-05-26 KR KR1020217042734A patent/KR20220041782A/ko active Pending
- 2020-05-26 EP EP20729830.8A patent/EP3975990A1/en active Pending
- 2020-05-26 WO PCT/IB2020/054984 patent/WO2020240417A1/en not_active Ceased
- 2020-05-27 TW TW109117742A patent/TWI757753B/zh active
- 2020-05-27 UY UY0001038717A patent/UY38717A/es not_active Application Discontinuation
- 2020-05-27 AR ARP200101496A patent/AR119021A1/es not_active Application Discontinuation
-
2021
- 2021-11-28 IL IL288503A patent/IL288503A/en unknown
-
2025
- 2025-09-30 US US19/345,133 patent/US20260027176A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020240417A1 (en) | 2020-12-03 |
| KR20220041782A (ko) | 2022-04-01 |
| AR119021A1 (es) | 2021-11-17 |
| TW202110472A (zh) | 2021-03-16 |
| IL288503A (en) | 2022-01-01 |
| TWI757753B (zh) | 2022-03-11 |
| SG11202112888RA (en) | 2021-12-30 |
| AU2020284587A1 (en) | 2022-01-06 |
| UY38717A (es) | 2020-11-30 |
| US12453754B2 (en) | 2025-10-28 |
| EA202193257A1 (ru) | 2022-03-10 |
| PH12021552976A1 (en) | 2022-07-04 |
| AU2020284587B2 (en) | 2025-09-18 |
| BR112021023904A2 (pt) | 2022-02-01 |
| US20220265760A1 (en) | 2022-08-25 |
| US20260027176A1 (en) | 2026-01-29 |
| JP2022535694A (ja) | 2022-08-10 |
| JP7664855B2 (ja) | 2025-04-18 |
| EP3975990A1 (en) | 2022-04-06 |
| CA3141456A1 (en) | 2020-12-03 |
| CN114144169A (zh) | 2022-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014540A (es) | Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama. | |
| CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
| CL2023002108A1 (es) | Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso. | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| NI201700001A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
| PH12020552080A1 (en) | Dll3-cd3 bispecific antibodies | |
| CL2019003266A1 (es) | Anticuerpos anti-sirpalfa. | |
| MX2021014286A (es) | Proteinas multiespecificas. | |
| CL2021000316A1 (es) | Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso | |
| AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
| PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| EA201891083A1 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
| MX2019010040A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| NI201700012A (es) | Inhibidores de la proteina quinasa c y métodos de su uso | |
| CL2021001260A1 (es) | Anticuerpos anti-sirpa humanizados | |
| MX2017014056A (es) | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. | |
| DOP2017000052A (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso | |
| PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| DOP2016000282A (es) | Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1) | |
| MX2022006132A (es) | Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco. | |
| CL2020003044A1 (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
| BR112022000120A2 (pt) | Projeto e sínteses eficientes de conjugados de lipídeo-fluoresceína para terapia de células car-t | |
| PL423259A1 (pl) | Koniugaty przeciwciało-ureaza dla celów terapeutycznych | |
| PE20151757A1 (es) | Anticuerpos anti-cd52 |